{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:07:59Z","timestamp":1785550079061,"version":"3.56.0"},"reference-count":19,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2019KY241"],"award-info":[{"award-number":["2019KY241"]}]},{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["2020KY1040"],"award-info":[{"award-number":["2020KY1040"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Int Med Res"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:p>Carbohydrate antigen 19-9 (CA19-9) and cytokeratin 19 fragment (CYFRA21-1) are widely used as tumor markers in clinical practice and are increased in many neoplasms. However, although increased serum CA19-9 levels have been found in some Japanese patients with renal urothelial carcinoma (UC), they have not been detected in patients from other countries or regions, and increased serum CYFRA21-1 levels haves not been reported in patients with renal UC. We analyzed serum CA19-9 and CYFRA21-1 levels in two patients with renal UC and monitored the changes in levels during postoperative follow-up. Both cases with renal pelvis UC had high levels of serum CA19-9 and CYFRA21-1, which decreased to within normal ranges after successful surgery, suggesting a causal relationship between renal UC and increased serum CA19-9 and CYFRA21-1. Because serum levels of CA19-9 and CYFRA21-1 are increased in many neoplastic diseases, they may not be reliable tumor markers for the screening and diagnosis of renal UC. However, they may be useful noninvasive indicators for assessing treatment effects in patients with renal pelvis UC with elevated pretreatment serum CA19-9 or CYFRA21-1.<\/jats:p>","DOI":"10.1177\/03000605211002692","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:45:54Z","timestamp":1616460354000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["High serum levels of CA 19-9 and CYFRA21-1 caused by renal pelvis urothelial carcinoma: a report of two cases"],"prefix":"10.1177","volume":"49","author":[{"given":"Guolin","family":"Yin","sequence":"first","affiliation":[{"name":"Department of Urology, Taizhou First People\u2019s Hospital, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Taizhou First People\u2019s Hospital, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Taizhou First People\u2019s Hospital, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7545-642X","authenticated-orcid":false,"given":"Zaixing","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Taizhou First People\u2019s Hospital, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"bibr1-03000605211002692","doi-asserted-by":"crossref","unstructured":"Lee T, Teng TZJ and Shelat VG. Carbohydrate antigen 19-9 - tumor marker: past, present, and future.\n                      World J Gastrointest Surg\n                      2020; 12: 468\u2013490.","DOI":"10.4240\/wjgs.v12.i12.468"},{"key":"bibr2-03000605211002692","doi-asserted-by":"crossref","unstructured":"Fu L, Wang R, Yin L, et al. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: a meta-analysis.\n                      Int J Biol Markers\n                      2019; 34: 251\u2013261.","DOI":"10.1177\/1724600819868234"},{"key":"bibr3-03000605211002692","doi-asserted-by":"crossref","unstructured":"Huang YL, Chen J, Yan W, et al. Diagnostic accuracy of cytokeratin-19 fragment (CYFRA21-1) for bladder cancer: a systematic review and meta-analysis.\n                      Tumour Biol\n                      2015; 36: 3137\u20133145.","DOI":"10.1007\/s13277-015-3352-z"},{"key":"bibr4-03000605211002692","doi-asserted-by":"crossref","unstructured":"Bian W and Xu Z. Combined assay of CYFRA21-1, telomerase and vascular endothelial growth factor in the detection of bladder transitional cell carcinoma.\n                      Int J Urol\n                      2007; 14: 108\u2013111.","DOI":"10.1111\/j.1442-2042.2007.01670.x"},{"key":"bibr5-03000605211002692","doi-asserted-by":"publisher","DOI":"10.1159\/000281648"},{"key":"bibr6-03000605211002692","first-page":"55","volume":"38","author":"Fujii Y","year":"1992","journal-title":"Hinyokika Kiyo"},{"key":"bibr7-03000605211002692","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.1996.tb00522.x"},{"key":"bibr8-03000605211002692","first-page":"961","volume":"42","author":"Miyoshi Y","year":"1996","journal-title":"Hinyokika Kiyo"},{"key":"bibr9-03000605211002692","first-page":"406","volume":"88","author":"Noto K","year":"1997","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"bibr10-03000605211002692","first-page":"495","volume":"43","author":"Sugaya Y","year":"1997","journal-title":"Hinyokika Kiyo"},{"key":"bibr11-03000605211002692","first-page":"653","volume":"44","author":"Iwata H","year":"1998","journal-title":"Hinyokika Kiyo"},{"key":"bibr12-03000605211002692","first-page":"191","volume":"47","author":"Taki T","year":"2001","journal-title":"Hinyokika Kiyo"},{"key":"bibr13-03000605211002692","first-page":"637","volume":"50","author":"Matsuoka Y","year":"2004","journal-title":"Hinyokika Kiyo"},{"key":"bibr14-03000605211002692","first-page":"203","volume":"58","author":"Itami Y","year":"2012","journal-title":"Hinyokika Kiyo"},{"key":"bibr15-03000605211002692","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13122"},{"key":"bibr16-03000605211002692","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2010.02671.x"},{"key":"bibr17-03000605211002692","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.07.036"},{"key":"bibr18-03000605211002692","first-page":"251","volume":"10","author":"Miyake M","year":"2018","journal-title":"Res Rep Urol"},{"key":"bibr19-03000605211002692","doi-asserted-by":"publisher","DOI":"10.4103\/0974-7796.95555"}],"container-title":["Journal of International Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605211002692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03000605211002692","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03000605211002692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:48:23Z","timestamp":1777459703000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03000605211002692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1177\/03000605211002692"],"URL":"https:\/\/doi.org\/10.1177\/03000605211002692","relation":{},"ISSN":["0300-0605","1473-2300"],"issn-type":[{"value":"0300-0605","type":"print"},{"value":"1473-2300","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"article-number":"03000605211002692"}}